New drug combo tested for aggressive blood cancer
NCT ID NCT03629171
Summary
This study is testing a combination of two chemotherapy drugs, CPX-351 and venetoclax, for adults with acute myeloid leukemia (AML) that has come back after treatment or did not respond to initial therapy. The main goal is to see if this combination can put the cancer into remission and is safe for patients. Researchers will also track how long patients live without the cancer getting worse and look for biological signs of how the treatment works.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT ACUTE MYELOID LEUKEMIA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
M D Anderson Cancer Center
RECRUITINGHouston, Texas, 77030, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.